Dietrich, Pierre-Yves

 
Title Year Hits Downloads
Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread 2021 16 1
Oncologie : naviguer la pandémie de COVID-19 et garder le cap 2020 63 0
Une période de craintes et de défis : vers un monde meilleur ? 2020 53 0
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients 2020 75 25
Resources-stratified guidelines for classical hodgkin lymphoma 2020 71 25
Journée du cancer : mobiliser autour de la prévention 2020 53 0
Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment 2020 125 36
An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin 2020 148 78
Stratégies de vaccination thérapeutique dans le glioblastome 2020 31 29
Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma 2020 111 75
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool 2020 34 15
Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma 2020 114 53
Immunologic clearance of a BK virus-associated metastatic renal allograft carcinoma 2020 106 118
Actively personalized vaccination trial for newly diagnosed glioblastoma 2019 292 12
Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma 2019 54 23
Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients 2019 142 82
De sérieuses préoccupations qui ne cachent pas nos espoirs 2019 135 13
Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma 2019 195 1
Peptides as cancer vaccines 2019 233 4
Current strategies for vaccination in glioblastoma 2019 176 5
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients 2019 478 222
« Docteur, je jeûne lors de la chimiothérapie » : illusion ou nouvelle réalité clinique ? 2018 289 132
Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors 2018 377 6
De vrais espoirs et de sérieuses préoccupations 2018 173 2
Prise en charge de la sexualité chez les patients oncologiques: Un projet de recherche au sein des Hôpitaux universitaires de Genève 2018 138 24
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma 2018 401 155
Médecine sexuelle et cancers : une main tendue vers l’humain 2018 146 46
Onco-sexologie : un regard au cœur des patients 2018 109 27
Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists 2018 302 2
CAR T-Cell Therapies in Glioblastoma: A First Look 2018 370 2
Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models 2018 164 1
Learning from the past to design better trials in second-line treatment for mesothelioma patients 2018 156 58
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma 2018 252 1
Prophylactic Cranial Irradiation in Stage III Non-Small-Cell Lung Cancer: Overall Survival Should Not Necessarily Be the Final End Point 2018 240 0
Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland 2018 291 112
Diagnosis and treatment of follicular lymphoma: an update 2018 323 126
Prolonged Versus Short-Duration Use of Nasogastric Tubes in Patients with Head and Neck Cancer During Radiotherapy Alone or Combined Chemoradiotherapy 2018 235 200
L’accès à l’innovation 2017 217 0
Identification of a novel population of highly cytotoxic c-Met-expressing CD8(+) T lymphocytes 2017 371 4
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial 2017 235 1
Immunothérapie des gliomes : illusion ou espoir ? 2017 236 0
Early closure of fistula using neo-adjuvant intra-arterial chemotherapy in locally advanced anal cancer 2017 331 0
8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016 2017 332 3
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma 2017 335 119
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma 2017 282 5
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients 2017 275 0
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies 2017 387 9
ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells 2017 400 10
A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells 2017 336 109
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants 2016 429 119
Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes 2016 304 229
Hypoxia and antitumor CD8(+) T cells: An incompatible alliance? 2016 303 132
Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis 2016 378 124
Ipilimumab-related hypophysitis may precede severe CNS immune attack 2016 294 0
Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness 2016 322 3
Progrès dans l’immunothérapie des tumeurs cérébrales : difficultés et perspectives 2016 156 2
Cell-penetrating peptides-the Swiss Army knife of cancer vaccines 2016 443 202
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? 2016 295 159
Medulloblastoma in children and adults: one distinct disease entity? 2016 256 24
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing 2016 381 506
Chimiothérapie de maintenance : futile ou utile ? 2015 271 53
Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review 2015 316 0
La société face au cancer : prises de conscience et initiatives citoyennes 2015 215 47
Lymphome cérébral : une présentation classique ? 2015 202 115
Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity 2015 405 9
Aggressiveness of cancer treatment in patients hospitalized in a supportive care unit 2015 480 1
Immunotherapy of Brain Tumors 2015 338 0
Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells 2015 323 7
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome 2015 273 95
Immunotherapy for glioma: from illusion to realistic prospects? 2014 968 381
Création du Centre du cancer de la prostate des HUG 2014 508 2
Extrachromosomal driver mutations in glioblastoma and low-grade glioma 2014 509 104
Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response 2014 511 288
Fine-needle aspiration biopsy for the diagnosis of metastatic type B thymoma to lymph nodes: A case report 2014 470 1
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma 2014 327 60
Injecting hope into brain cancer treatment: is immunotherapy the way forward? 2014 224 0
Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies 2013 360 0
Neuropathies associées aux paraprotéinémies (gammapathies monoclonales) 2013 246 0
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients 2013 393 450
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy 2013 469 0
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) 2013 384 0
Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours 2013 484 245
The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma 2013 485 6
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status 2012 383 930
Plasmablastic lymphoma clinically presenting in the urinary tract 2012 454 0
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy 2012 455 809
Takotsubo syndrome secondary to adrenal adenocarcinoma: cortisol as a possible culprit 2012 462 5
Visceral Kaposi's Sarcoma Related to Human Herpesvirus-8 in Liver Transplant Recipient: Case Report and Literature Review 2012 444 217
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma 2012 420 351
A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients 2012 472 0
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma 2012 493 453
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival 2012 402 2
Soin nutritionnel intégré au soin oncologique : un besoin d'optimisation 2011 719 427
Oncology ESAB 2011 2011 418 8
Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis 2011 478 0
Prevention of CNS relapse in diffuse large B-cell lymphoma 2011 397 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients 2011 778 503
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study 2011 555 7
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report 2011 458 93
Recurrent Syncope due to Esophageal Squamous Cell Carcinoma 2011 476 215
Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma 2010 472 1
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development 2010 422 3
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma 2010 421 0
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98 2010 373 0
T-cell immunotherapy for malignant glioma: toward a combined approach 2010 468 2
Marker-independent identification of glioma-initiating cells 2010 392 0
Tumors that look for their springtime in APRIL 2009 440 0
Diagnostic precision of image-guided multisampling core needle biopsy of suspected lymphomas in a primary care hospital 2009 451 0
Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant 2009 432 1
Intrathecal MTX for DLBCL: from an inappropriate prophylactic tradition to a medical error? 2009 413 1
Limits of CD133 as a marker of glioma self-renewing cells 2009 411 0
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers 2008 388 0
Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef 2008 423 0
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma 2008 480 2
Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome 2008 404 0
Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance 2008 421 120
Bortezomib-induced skin eruption 2008 402 2
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva) 2008 326 1
Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system 2008 719 387
Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes 2008 417 11
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas 2006 446 0
Cytomegalovirus colitis--a severe complication after standard chemotherapy 2002 426 0
40941 9886